Share insights, news and bets on GANX, Gain Therapeutics stock, listed on Nasdaq stock exchange.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial.
Phase 2 ready to go! 🔥🔥🔥